Oncternal Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ONCT and buy or sell other stocks, ETFs, and their options commission-free!About ONCT
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Its product pipeline include Zilovertamab, ONCT-216, ONCT-808 and ONCT-534.
CEOJames B. Breitmeyer, MD, PhD
CEOJames B. Breitmeyer, MD, PhD
Employees—
Employees—
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1997
Founded1997
Employees—
Employees—
ONCT Key Statistics
Market cap1.56M
Market cap1.56M
Price-Earnings ratio-0.05
Price-Earnings ratio-0.05
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.5266
52 Week high$0.5266
52 Week low$0.5266
52 Week low$0.5266
Stock Snapshot
With a market cap of 1.56M, Oncternal Therapeutics(ONCT) trades at $0.53. The stock has a price-to-earnings ratio of -0.05.
Oncternal Therapeutics(ONCT) stock opened on 2025-12-21 at —. The price climbed to — and dipped to —.
Oncternal Therapeutics(ONCT) shares are trading with a volume of 0.
During the past year, Oncternal Therapeutics(ONCT) stock moved between $0.53 at its lowest and $0.53 at its peak.
During the past year, Oncternal Therapeutics(ONCT) stock moved between $0.53 at its lowest and $0.53 at its peak.
People also own
Based on the portfolios of people who own ONCT. This list is generated using Robinhood data, and it’s not a recommendation.